Trailblazer Webinar: Overcoming Financial Toxicity In Oncology Clinical Trials

Participation in clinical trials among adult cancer patients remains low, with fewer than 5% taking part. According to reports, this statistic is largely attributed to the formidable financial challenges and costs associated with oncology clinical trials, which often deter eligible candidates.

But, Greenphire has extended an invitation to be a part of the change. In this Trailblazer Webinar, viewers can watch as the following speakers shed light on innovative strategies leading the way toward a more favorable patient experience and enhanced study results:

• Jim Murphy, CEO, Greenphire
• Mark Fleury, Principal, Policy Development, Emerging Science, American Cancer Society Cancer Action Network
• Tim Dorsey, Team Lead, Product Training, Greenphire
• Elizabeth Barksdale, Senior Director of Regulatory Affairs and Scientific Policy, LUNGevity

Discover the historical struggles of oncology research due to financial toxicity, explore industry initiatives aimed at eliminating these barriers, and learn about ongoing advocacy efforts in Washington, D.C., focused on reducing the tax implications of patient stipends.